Five IPOs and Three SPACs Priced This Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 56 minutes ago
0mins
Should l Buy SUJA?
Source: renaissancecapital
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUJA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUJA
Wall Street analysts forecast SUJA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 17.850
Low
Averages
High
Current: 17.850
Low
Averages
High

No data
About SUJA
Suja Life, Inc. is a beverage platform. The Company operates at the intersection of health, taste, and trust, offering cold-pressed juices, wellness shots, and functional sodas that have become an essential part of consumers' everyday routines. Its brands include Suja Organic, Vive Organic, and Slice. Suja Organic is its flagship brand, known for its organic cold-pressed juices and wellness shots.it includes a green juice platform, boosted juice platform, refreshers platform, and wellness shots platform. Vive Organic is a wellness shot brand, known for the functional shot category with its doctor-crafted formulations and redefining how consumers approach proactive wellness. It offers an immunity boost platform, energy boost platform, and pure boost platform. Slice offers an original better-for-you soda, made with 10% real fruit juice and also with prebiotics, probiotics, postbiotics, reduced sugar, and no artificial ingredients.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- IPO Fundraising Goal: Suja Life aims to raise $200 million by offering 8.9 million shares (2% secondary) at a price range of $21 to $24, intending to enhance its competitiveness in the health beverage market.
- Product Diversification: The company offers cold-pressed juices, wellness shots, and functional sodas through its Suja Organic, Vive Organic, and Slice brands, catering to various consumption occasions and solidifying its market position in functional beverages.
- Financial Performance: Suja Life reported $327 million in revenue for the 12 months ending December 31, 2025, indicating strong growth potential in the health beverage sector, with the IPO expected to provide funding for future expansion.
- Listing Plans: Suja Life plans to price its IPO during the week of May 4, 2026, and list on Nasdaq under the ticker SUJA, which is anticipated to attract investor interest in the health beverage industry.
See More
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
- Funding Size: Suja Life successfully raised $187 million by offering 8.9 million shares at $21 each, which is at the low end of the $21 to $24 range, indicating sustained market interest and demand for health-oriented beverages.
- Product Portfolio: The company focuses on functional and health-oriented drinks, with brands including Suja Organic, Vive Organic, and Slice, offering cold-pressed juices, wellness shots, and functional sodas designed for various consumption occasions, enhancing its competitive edge in the market.
- Production Capacity: Suja Life operates a vertically integrated cold-pressed beverage manufacturing facility in North America, ensuring high product quality and supply chain stability, thereby strengthening its position in the rapidly growing health beverage market.
- IPO Details: Based in Oceanside, CA, Suja Life will trade on Nasdaq under the ticker SUJA, with joint bookrunners including Goldman Sachs, Jefferies, and William Blair, reflecting strong backing in the capital markets.
See More








